Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines
For distribution outside the U.S. only
Azzalure also marketed as Dysport outside of the EU for the treatment of glabellar lines marks 10 year anniversary with more than 40 million treatments in the EU and US combined and approval in 72 countries.
Lausanne, Switzerland – April 4 – Galderma, Nestlé Skin Health’s medical solutions business, is proud to celebrate the significant milestone of the 10th anniversary of the Dysport® (abobotulinumtoxinA) for Injection (US) and Azzalure (EU) brands. 1 One of the world's most studied and original neuro toxin type A products, abobotulinumtoxinA marketed under the brand names Dysport and Azzalure, is a muscle relaxant used for aesthetic treatment of glabellar lines approved in more than 72 countries worldwide with over 40 million glabellar line treatments in Europe and the U.S. alone.2
Galderma’s long term focus on innovation, coupled with its close cooperation and long term partnership with healthcare professionals for Dysport and Azzalure has led to a decade of proven and safe use. Dysport and Azzalure, along with Galderma portfolio of Restylane dermal fillers, continue to deliver effective and proven aesthetic solutions to healthcare professionals and their patients, allowing specialists to customize a treatment plan that’s right for each individual.
“This significant milestone for Dysport and Azzalure signifies a partnership you can count on,” said Alexandre Brennan, Vice President, Aesthetics, Galderma, Switzerland. “The combination of the reliable muscle relaxant used for glabellar line treatment with our extensive training program for healthcare professionals GAIN (Galderma Aesthetic Injector Network), secure a strong foundation for the Dysport and Azzalure brands to continue to support the goals of healthcare professionals and patients now and in the future, count on us!”
1. Outside EU Azzalure is commercialized under the Dysport brand.
2. Enough Abobotulinum toxin type A produced for 40 million glabellar lines treatments (using approved dosage of 50 Speywood units/GL).
Galderma, Nestlé Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
Galderma media relations contact
Sébastien Cros, Head of Corporate Communications, [email protected]
© 2019 Nestle Skin Health SA. The Dysport® trademark is used under license. All trademarks are the property of their respective owners.